搜索
Addex Therapeutics Ltd
ADXN添加自选
7.090USD
+0.430+6.46%
收盘 05/15, 16:00（美东）报价延迟15分钟
12.51M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.46%
5天
+3.65%
1月
+4.11%
6月
-16.29%
今年开始到现在
-8.16%
1年
-16.59%
TradingKey Addex Therapeutics Ltd股票评分
单位: USD 更新时间: 2026-05-15操作建议
Addex Therapeutics Ltd当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名227/382位。机构持股占比非常低，近一月多位分析师给出公司评级为。最高目标价30.00。中期看，股价处于平稳状态。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Addex Therapeutics Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Addex Therapeutics Ltd亮点
亮点风险
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
业绩增长期
公司处于发展阶段，最新年度总收入38.33K美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-0.78，处于3年历史低位
机构减仓
最新机构持股454.00股，环比减少96.54%
分析师目标
根据
0
位分析师
--
评级
30.000
目标均价
+243.64%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Addex Therapeutics Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Addex Therapeutics Ltd简介
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
公司代码ADXN
公司Addex Therapeutics Ltd
CEODyer (Tim)
网址https://www.addextherapeutics.com/en/
相关品种
